[1]
Holdorff B. Friedrich Heinrich Lewy (1885-1950) and his work. Journal of the history of the neurosciences. 2002 Mar:11(1):19-28
[PubMed PMID: 12012571]
[2]
Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1988 Aug:8(8):2804-15
[PubMed PMID: 3411354]
[3]
Yavich L, Tanila H, Vepsäläinen S, Jäkälä P. Role of alpha-synuclein in presynaptic dopamine recruitment. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2004 Dec 8:24(49):11165-70
[PubMed PMID: 15590933]
[4]
Yavich L,Jäkälä P,Tanila H, Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice. Journal of neurochemistry. 2006 Nov
[PubMed PMID: 16824047]
[5]
Hou X, Fiesel FC, Truban D, Castanedes Casey M, Lin WL, Soto AI, Tacik P, Rousseau LG, Diehl NN, Heckman MG, Lorenzo-Betancor O, Ferrer I, Arbelo JM, Steele JC, Farrer MJ, Cornejo-Olivas M, Torres L, Mata IF, Graff-Radford NR, Wszolek ZK, Ross OA, Murray ME, Dickson DW, Springer W. Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. Autophagy. 2018:14(8):1404-1418. doi: 10.1080/15548627.2018.1461294. Epub 2018 Jul 28
[PubMed PMID: 29947276]
Level 3 (low-level) evidence
[6]
Paiva I, Jain G, Lázaro DF, Jerčić KG, Hentrich T, Kerimoglu C, Pinho R, Szegő ÈM, Burkhardt S, Capece V, Halder R, Islam R, Xylaki M, Caldi Gomes LA, Roser AE, Lingor P, Schulze-Hentrich JM, Borovečki F, Fischer A, Outeiro TF. Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi function. Neurobiology of disease. 2018 Nov:119():121-135. doi: 10.1016/j.nbd.2018.08.001. Epub 2018 Aug 6
[PubMed PMID: 30092270]
[7]
Hogan DB, Fiest KM, Roberts JI, Maxwell CJ, Dykeman J, Pringsheim T, Steeves T, Smith EE, Pearson D, Jetté N. The Prevalence and Incidence of Dementia with Lewy Bodies: a Systematic Review. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 2016 Apr:43 Suppl 1():S83-95. doi: 10.1017/cjn.2016.2. Epub
[PubMed PMID: 27307129]
Level 1 (high-level) evidence
[8]
Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA neurology. 2013 Nov:70(11):1396-402. doi: 10.1001/jamaneurol.2013.3579. Epub
[PubMed PMID: 24042491]
[9]
Braak H, Del Tredici K. Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff. Journal of Parkinson's disease. 2017:7(s1):S71-S85. doi: 10.3233/JPD-179001. Epub
[PubMed PMID: 28282810]
[10]
Braak H, Müller CM, Rüb U, Ackermann H, Bratzke H, de Vos RA, Del Tredici K. Pathology associated with sporadic Parkinson's disease--where does it end? Journal of neural transmission. Supplementum. 2006:(70):89-97
[PubMed PMID: 17017514]
[11]
Jellinger KA, Is Braak staging valid for all types of Parkinson's disease? Journal of neural transmission (Vienna, Austria : 1996). 2018 Jun 25
[PubMed PMID: 29943229]
[12]
Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta neuropathologica. 2008 Jul:116(1):1-16. doi: 10.1007/s00401-008-0406-y. Epub 2008 Jul 1
[PubMed PMID: 18592254]
[13]
Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG, Arizona Parkinson's Disease Consortium. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta neuropathologica. 2009 Jun:117(6):613-34. doi: 10.1007/s00401-009-0538-8. Epub 2009 Apr 28
[PubMed PMID: 19399512]
[14]
Frigerio R, Fujishiro H, Ahn TB, Josephs KA, Maraganore DM, DelleDonne A, Parisi JE, Klos KJ, Boeve BF, Dickson DW, Ahlskog JE. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiology of aging. 2011 May:32(5):857-63. doi: 10.1016/j.neurobiolaging.2009.05.019. Epub 2009 Jun 26
[PubMed PMID: 19560232]
Level 3 (low-level) evidence
[15]
DelleDonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JE, Josephs KA, Frigerio R, Burnett M, Wszolek ZK, Uitti RJ, Ahlskog JE, Dickson DW. Incidental Lewy body disease and preclinical Parkinson disease. Archives of neurology. 2008 Aug:65(8):1074-80. doi: 10.1001/archneur.65.8.1074. Epub
[PubMed PMID: 18695057]
[16]
Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta neuropathologica. 2008 Apr:115(4):437-44. doi: 10.1007/s00401-008-0345-7. Epub 2008 Feb 9
[PubMed PMID: 18264713]
[17]
Tan JM, Wong ES, Lim KL. Protein misfolding and aggregation in Parkinson's disease. Antioxidants & redox signaling. 2009 Sep:11(9):2119-34
[PubMed PMID: 19243238]
[18]
Dugger BN, Dickson DW. Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta neuropathologica. 2010 Nov:120(5):633-9. doi: 10.1007/s00401-010-0739-1. Epub 2010 Aug 19
[PubMed PMID: 20721565]
[19]
Tanji K, Odagiri S, Miki Y, Maruyama A, Nikaido Y, Mimura J, Mori F, Warabi E, Yanagawa T, Ueno S, Itoh K, Wakabayashi K. p62 Deficiency Enhances α-Synuclein Pathology in Mice. Brain pathology (Zurich, Switzerland). 2015 Sep:25(5):552-64. doi: 10.1111/bpa.12214. Epub 2014 Nov 20
[PubMed PMID: 25412696]
[20]
Odagiri S, Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K. Autophagic adapter protein NBR1 is localized in Lewy bodies and glial cytoplasmic inclusions and is involved in aggregate formation in α-synucleinopathy. Acta neuropathologica. 2012 Aug:124(2):173-86. doi: 10.1007/s00401-012-0975-7. Epub 2012 Apr 7
[PubMed PMID: 22484440]
[21]
Li X, Lee J, Parsons D, Janaurajs K, Standaert DG. Evaluation of TorsinA as a target for Parkinson disease therapy in mouse models. PloS one. 2012:7(11):e50063. doi: 10.1371/journal.pone.0050063. Epub 2012 Nov 21
[PubMed PMID: 23185535]
[22]
Graham SF, Rey NL, Yilmaz A, Kumar P, Madaj Z, Maddens M, Bahado-Singh RO, Becker K, Schulz E, Meyerdirk LK, Steiner JA, Ma J, Brundin P. Biochemical Profiling of the Brain and Blood Metabolome in a Mouse Model of Prodromal Parkinson's Disease Reveals Distinct Metabolic Profiles. Journal of proteome research. 2018 Jul 6:17(7):2460-2469. doi: 10.1021/acs.jproteome.8b00224. Epub 2018 May 25
[PubMed PMID: 29762036]
[23]
Licker V, Turck N, Kövari E, Burkhardt K, Côte M, Surini-Demiri M, Lobrinus JA, Sanchez JC, Burkhard PR. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis. Proteomics. 2014 Mar:14(6):784-94. doi: 10.1002/pmic.201300342. Epub 2014 Feb 18
[PubMed PMID: 24449343]
[24]
Dölle C, Flønes I, Nido GS, Miletic H, Osuagwu N, Kristoffersen S, Lilleng PK, Larsen JP, Tysnes OB, Haugarvoll K, Bindoff LA, Tzoulis C. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nature communications. 2016 Nov 22:7():13548. doi: 10.1038/ncomms13548. Epub 2016 Nov 22
[PubMed PMID: 27874000]
[25]
Tzoulis C,Schwarzlmüller T,Biermann M,Haugarvoll K,Bindoff LA, Mitochondrial DNA homeostasis is essential for nigrostriatal integrity. Mitochondrion. 2016 May
[PubMed PMID: 26979109]
[26]
Beyer K, Domingo-Sàbat M, Ariza A. Molecular pathology of Lewy body diseases. International journal of molecular sciences. 2009 Mar:10(3):724-45. doi: 10.3390/ijms10030724. Epub 2009 Feb 26
[PubMed PMID: 19399218]
[27]
Weng M, Xie X, Liu C, Lim KL, Zhang CW, Li L. The Sources of Reactive Oxygen Species and Its Possible Role in the Pathogenesis of Parkinson's Disease. Parkinson's disease. 2018:2018():9163040. doi: 10.1155/2018/9163040. Epub 2018 Sep 2
[PubMed PMID: 30245802]
[28]
Franco-Iborra S, Vila M, Perier C. Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease. Frontiers in neuroscience. 2018:12():342. doi: 10.3389/fnins.2018.00342. Epub 2018 May 23
[PubMed PMID: 29875626]
Level 2 (mid-level) evidence
[29]
Duda J,Pötschke C,Liss B, Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease. Journal of neurochemistry. 2016 Oct
[PubMed PMID: 26865375]
[30]
Van Laar VS, Roy N, Liu A, Rajprohat S, Arnold B, Dukes AA, Holbein CD, Berman SB. Glutamate excitotoxicity in neurons triggers mitochondrial and endoplasmic reticulum accumulation of Parkin, and, in the presence of N-acetyl cysteine, mitophagy. Neurobiology of disease. 2015 Feb:74():180-93. doi: 10.1016/j.nbd.2014.11.015. Epub 2014 Dec 3
[PubMed PMID: 25478815]
[31]
Jellinger KA, Korczyn AD. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? BMC medicine. 2018 Mar 6:16(1):34. doi: 10.1186/s12916-018-1016-8. Epub 2018 Mar 6
[PubMed PMID: 29510692]
[32]
Kalia LV. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid. Parkinsonism & related disorders. 2019 Feb:59():21-25. doi: 10.1016/j.parkreldis.2018.11.016. Epub 2018 Nov 15
[PubMed PMID: 30466800]
[33]
Algarni MA, Stoessl AJ. The role of biomarkers and imaging in Parkinson's disease. Expert review of neurotherapeutics. 2016:16(2):187-203. doi: 10.1586/14737175.2016.1135056. Epub 2016 Feb 1
[PubMed PMID: 26829357]
[34]
Farotti L, Paciotti S, Tasegian A, Eusebi P, Parnetti L. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease. Expert review of molecular diagnostics. 2017 Aug:17(8):771-780. doi: 10.1080/14737159.2017.1341312. Epub 2017 Jun 19
[PubMed PMID: 28604235]
Level 1 (high-level) evidence
[35]
Parnetti L, Cicognola C, Eusebi P, Chiasserini D. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis. Biomarkers in medicine. 2016:10(1):35-49. doi: 10.2217/bmm.15.107. Epub 2015 Dec 8
[PubMed PMID: 26643452]